The immediate early transcription factor nuclear factor (IjBs) kappa B (NF-jB) is crucially involved in the regulation of numerous physiological or pathophysiological processes such as inflammation and tumourigenesis. Therefore, the control of NF-jB activity, which is mainly regulated by signal-induced degradation of cytoplasmic inhibitors of NF-jB (IjBs), is of high relevance. One known alternative pathway of NF-jB regulation is the stimulus-induced proteasomal degradation of RelB, a component of the NF-jB dimer. Here, we identified the serine/threonine protein kinase glycogen synthase kinase-3b (GSK-3b) as a critical signalling component leading to RelB degradation. In Jurkat leukaemic T cells as well as in primary human T cells, tetradecanoylphorbolacetate/ionomycinand CD3/CD28-induced RelB degradation were impaired by a GSK-3b-specific pharmacological inhibitor, an ectopically expressed dominant-negative GSK-3b mutant and by small-interfering RNA-mediated silencing of GSK-3b expression. Furthermore, a physical interaction between RelB and GSK-3b was shown by co-immunoprecipitation, which was already notable in unstimulated cells. Most importantly, as demonstrated by in vitro kinase assays, human RelB is inducibly phosphorylated by GSK-3b, indicating a direct substrate-enzyme relationship. The serine residue 552 is a target of GSK-3b-mediated phosphorylation in vitro and in vivo. We conclude that GSK-3b is a crucial regulator of RelB degradation, stressing the relevant linkage between the NF-jB system and GSK-3b.
The pleiotropic transcription factor nuclear factor kappa B (NF-kB) regulates many physiological and pathophysiological processes, including innate and adaptive immune responses, inflammation, proliferation, apoptosis and tumourigenesis (Neumann and Naumann, 2007) , which are closely interconnected (Karin and Greten, 2005) . In addition to the crucial role of NF-kB in inflammation-associated tumourigenesis, recent studies point to a pivotal role of deregulated NF-kB activity in the pathogenesis of leukaemia and lymphoma (Compagno et al., 2009; Kato et al., 2009) , as well as of solid tumours (Barbie et al., 2009; Kato et al., 2009; Meylan et al., 2009) .
The regulation of NF-kB activity is mainly mediated by the signal-induced proteasomal degradation of cytoplasmic inhibitors of NF-kB (IkBs). The NF-kB activating signals such as proinflammatory cytokines (for example, tumour necrosis factor-a) or phorbol esters (for example, tetradecanoylphorbolacetate) converge at the IkB kinase (IKK) complex consisting of two functionally non-redundant kinases, IKK-a (IKK1) and IKK-b (IKK2) and a regulatory subunit, IKK-g (NEMO) . This IKK complex induces the site-specific phosphorylation of IkBs, a prerequisite for subsequent ubiquitination, which finally tags IkBs for proteasomal degradation. NF-kB can now translocate into the nucleus, where it regulates the expression of genes critical for cell fate-determining processes (Neumann and Naumann, 2007) .
The stimulus-induced RelB degradation is an alternative IkB-independent mechanism of NF-kB regulation known to occur not only in T cells but also in other lymphoid and non-lymphoid cells (Marienfeld et al., 2001 (Marienfeld et al., , 2003 . RelB is one of the five mammalian Rel proteins of which the NF-kB dimer is composed. Stimulus-induced downregulation of RelB is mediated by the 26S proteasome, as demonstrated by the inhibition of this process using specific proteasomal inhibitors. Further, RelB degradation is phosphorylation dependent. Mutation of two critical phosphoacceptor amino acids (Thr84 and Ser552) leads to the stabilisation of the RelB molecule against degradation. Thus, RelB degradation resembles signal-induced IkB degradation in many ways, but there are also distinct differences. Both processes differ in their kinetics with RelB degradation being delayed compared with IkB degradation. Further, RelB degradation is signal specific and cannot be induced by tumour necrosis factor-a, a potent activator of NF-kB (Marienfeld et al., 2001) .
The ubiquitously expressed, multi-functional serine/ threonine kinase glycogen synthase kinase-3 (GSK-3) has a crucial role in diverse signalling pathways determining proliferation, differentiation and cell survival (Forde and Dale, 2007) . Two highly homologous GSK-3 isoforms, GSK-3a and GSK-3b, are encoded by distinct genes, share substrate specificity in vitro and regulate the activity of many substrates by phosphorylation. GSK-3b is a component of the b-catenin destruction complex. It phosphorylates b-catenin, which is a prerequisite for its ubiquitination and proteasomal degradation. Many of the GSK-3b targets are components of the transcriptional machinery (Vincent et al., 2008) , especially transcription factors such as c-Jun (de Groot et al., 1993) or c-Myc (Sears et al., 2000) . Phosphorylation of c-Myc targets this proto-oncoprotein for ubiquitin-mediated proteolysis (Sears et al., 2000) .
Aberrant regulation of GSK-3b has been implicated in many human pathologies including cancer (Billadeau, 2007; Dar et al., 2009 ). Thus, GSK-3b activity is tightly regulated through several mechanisms, including differential splicing and regulated subcellular localisation, interaction with scaffolding proteins and phosphorylation. N-terminal phosphorylation (S9 of GSK-3b) has an inhibitory effect, whereas phosphorylation of a specific tyrosine residue (Y216 of GSK-3b) activates GSK-3b (Forde and Dale, 2007) .
GSK-3b-and NF-kB-mediated signalling events are closely linked. The phenotype of GSK-3b-deficient mice (Hoeflich et al., 2000) is strikingly similar to the phenotype displayed by IKK-b-or RelA-deficient mice and characterized by embryonic death caused by increased apoptosis in the liver (Beg et al., 1995; Li et al., 1999) . Moreover, mouse embryonic fibroblasts derived from these animals are more sensitive towards tumour necrosis factor-a-induced apoptosis than wildtype fibroblasts because of the inability of these mouse embryonic fibroblasts to induce NF-kB (Hoeflich et al., 2000) . Another study demonstrated that GSK-3b has profound effects on NF-kB-mediated transcription in a gene-specific manner through a mechanism involving control of promoter-specific NF-kB recruitment (Steinbrecher et al., 2005) . GSK-3b can also phosphorylate p105, the precursor of p50/NF-kB1, thereby stabilizing this molecule (Demarchi et al., 2003) . GSK3b-mediated phosphorylation of RelA on Ser468 (Buss et al., 2004 ) is controversially discussed, as another study demonstrated that IKK-b is responsible for this phosphorylation event (Schwabe and Sakurai, 2005) .
The protein kinase C (PKC) inhibitor bisindolylmaleimide 1, which blocks the activity of most PKC isoforms (IC 50 value: 10 nM), is able to completely inhibit RelB degradation at higher concentrations. However, it was notable that a bisindolylmaleimide 1 concentration of 50 nM did not lead to a complete block of RelB degradation induced by tetradecanoylphorbolacetate/ionomycin (T þ I) stimulation of Jurkat T cells (Figure 1a ). This finding might be an indication for the involvement of other protein kinases. For a more detailed analysis, we performed inhibitor-screening experiments to identify PKC isoform(s) involved in signal-induced RelB degradation. We used different cell-permeable isoform-specific PKC inhibitors: Go¨6976 (Figure 1b) , Rottlerin, which also inhibits CaM kinase III (Figure 1c ) and RO-32-0432 ( Figure 1d ). As all PKC isoforms have distinct affinities for a given inhibitor, variation of inhibitor concentration enabled us to differentiate between the PKC species. The IC 50 values of different PKC isoforms for a specific inhibitor are displayed in Figures 1b-d . No effect on RelB degradation was seen with any of the PKC isoform-specific inhibitors (Figures 1b-d) . The effectiveness of the PKC-specific inhibitors in our experimental system was verified in control experiments (Supplementary Figure 1a) .
Bisindolylmaleimide 1 is not specific for PKCs, but also potently inhibits GSK-3b (IC 50 value: 170 nM). Therefore, this serine/threonine kinase might be the bisindolylmaleimide 1 target, whose inhibition leads to a block in RelB degradation. To verify this assumption, we tried to inhibit RelB degradation after T þ I stimulation of Jurkat T cells using the GSK-3b-selective inhibitor SB216763. Immunoblot analyses of cytoplasmic and nuclear protein extracts using RelB-specific antibodies (Abs) revealed a concentration-dependent inhibition of RelB degradation (Figure 1e ). Using a more physiological model, inhibition of RelB degradation was also notable in primary human CD4 þ T lymphocytes upon T þ I stimulation (Figure 1f ) or CD3/ CD28 co-stimulation (Figure 1g ). We conclude that GSK-3b, but not PKC, might be a critical component of the pathway(s) leading to signal-induced RelB degradation. A comprehensive overview of RelB levels detectable in the different inhibitor experiments is shown in the Supplementary Figures 1b-i. SB216763 is regarded to be an extremely selective, but not specific inhibitor for GSK-3b. A recent study demonstrated that this compound also inhibits other protein kinases such as ERK8 or PIM3 (Bain et al., 2007) . Thus, we tried to validate the hypothesis that GSK-3b is critically involved in RelB degradation by approaches using dominant-negative GSK-3b mutants or small-interfering RNA (siRNA)-mediated gene silencing. Three different forms of GSK-3b were ectopically expressed in Jurkat T cells. The expression vectors encoded a wild-type, full-length GSK-3b, a GSK-3b variant with a mutation leading to substitution of Ser9 with an alanine residue (S9A; constitutive-active), and a dominant-negative GSK-3b mutant containing a substitution at amino acid 85 (K85R). All ectopically expressed proteins were myc-tagged. The dominantnegative GSK-3b is expressed at lower levels, whereas the expression levels of the other two ectopically expressed GSK-3b forms were comparable to the concentration of endogenous GSK-3b in mock-transfected cells (Figure 2a ). In unstimulated Jurkat T cells, RelB As a third approach to prove the critical involvement of GSK-3b in RelB degradation, we employed three siRNA molecules targeting different regions of the GSK-3b mRNA. Transfection of siRNA-1 and -2 led to a strong suppression of GSK-3b protein expression in Jurkat T cells ( Figure 2c , left panel, upper row, lanes 4-9) with less than 10% of the original protein levels detectable in transfected cells. SiRNA-3 had no impact on GSK-3b protein expression ( Figure 2c , right panel, upper row, lanes 13-15) and was used as a control. Mock-and siRNA-3-transfected cells displayed no Figure 1 GSK-3b-but not PKC-specific pharmacological inhibitors block RelB degradation. Jurkat leukaemic T cells were pretreated for 30 min with the indicated concentrations of bisindolylmaleimide 1 (BIM-1) (a), and of the PKC isoformspecific inhibitors Go¨6976 (b), Rottlerin (c) and Ro-32-0432 (d) (all from Calbiochem, La Jolla, CA, USA). The concentrations of the inhibitors were chosen according to the IC 50 values of different PKC isoforms (see boxes). Cells were either left unstimulated or were stimulated for 30 min with TPA (20ng/ml) and ionomycin (1 mM) (T þ I) (both from Sigma-Aldrich, St Louis MO, USA). Whole-cellular extracts (20 mg per lane) were immunoblotted as described earlier (Marienfeld et al., 2001) and analysed using a RelB-specific Ab (C19, sc-226; Santa Cruz Biotechnology). After stripping, the membranes were probed with a b-tubulin-specific Ab (#2128, Cell Signaling, Beverly, MA, USA) as a control for equal loading. (e) Jurkat T cells pretreated with SB216763 (Sigma-Aldrich), a cell permeable GSK3-specific inhibitor (Forde and Dale, 2007) were subjected to subcellular fractionation as described earlier (Marienfeld et al., 2001) . The protein extracts were analysed as described above. As a loading control, the membranes containing cytoplasmic protein extracts were stripped and probed with an a-b-tubulin Ab. Equal loading of nuclear proteins was controlled by probing the respective membranes with an Ab specific for TATA binding protein (TBP) (ab818, Abcam, Cambridge, UK) and by reversible staining of the membranes with Ponceau S. Abbreviations: C, cytoplasmic protein extract and N, nuclear protein extract. (f) Primary human CD4 þ T lymphocytes were prepared by MACS-sorting using the Auto-MACS system according to the manufacturer's instructions (Miltenyi Biotech, Bergisch-Gladbach, Germany). Primary T cells were pretreated with SB216763, stimulated with T þ I and analysed as described above. (g) Primary human T cells either left untreated or pretreated with SB216763 were subjected to CD3/CD28 co-stimulation as previously described (Marienfeld et al., 2001) . For stimulation, the following functional grade purified Abs were used: a-human CD3 (#16-0038) and a-human CD28 (#16-0289). Both Abs were from NatuTec/eBioscience (Frankfurt, Germany). Three independent experiments were performed for a-g. A statistical evaluation is given in the Supplementary Figures 1b-g . Figure 2 GSK-3b is a crucial mediator of RelB degradation. (a) Expression vectors encoding myc-tagged wild-type (wt), constitutiveactive (S9A) and dominant-negative (K85R) GSK-3b variants were transfected into Jurkat leukaemic T cells using Lipofectamine (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Cells were either left unstimulated or stimulated with T þ I for 30 min. Whole-cellular extracts were prepared and the expression of endogenous, and ectopically expressed GSK-3b was analysed by immunoblotting using a GSK-3b-specific Ab (BD Bioscience Pharmingen, San Jose, CA, USA; upper row). RelB degradation was investigated using a RelB-specific Ab (middle row). Finally, equal loading was confirmed by re-probing the membrane with a b-tubulin-specific Ab (D10, sc-5274; Santa Cruz Biotechnology; lower row). (b) Densitometric and subsequent statistical evaluation of T þ I-induced changes in RelB levels in Jurkat cells either mock-transfected or transfected with different forms of GSK-3b (wild-type, constitutive-active or dominant-negative). Three independent experiments were performed. The signal intensities were normalised relative to the respective loading controls. Statistical analysis was performed using Student's t-test. Asterisks indicate a significant difference from unstimulated cells (*Po0.01; **Po0.001) (c) Three different siRNAs were electroporated into Jurkat Statistical analysis was performed using Student's t-test. Asterisks indicate a significant difference from unstimulated cells (GSK-3b: *Po0.05; **Po0.001; RelB: *Po0.005). (e) Primary human T cells were mock transfected or transfected with the respective siRNA using the Amaxa Human T cell Nucleofector Kit as described by the manufacturer's nucleofection protocol (Lonza, Cologne, Germany). The transfected cells were treated as in (c). (f) Changes of GSK-3b and RelB concentrations upon silencing of GSK-3b expression by gene-specific siRNAs in primary human T lymphocytes (T þ I stimulation). Three independent experiments were performed. Statistical analysis was performed using Student's t-test. Asterisks indicate a significant difference from unstimulated cells (GSK-3b: *Po0.05; **Po0.001; RelB: *Po0.01; **Po0.001).
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The partial silencing of GSK-3b expression by siRNA-2 resulted in only a partial or no inhibition of RelB degradation (Figure 2e , lanes 7-9). Both findings demonstrate that GSK-3b is indeed a critical component involved in this process. The results of a detailed densitometric evaluation and subsequent statistical analysis of RelB expression in Jurkat cells, ectopically expressing different GSK-3b forms is shown in Figure 2b . The same analysis was performed with T cells, in which GSK-3b expression was downregulated by siRNA-mediated gene silencing (Figures 2d and f) . Taken together, we have identified GSK-3b as the first signalling component of the pathway(s) leading to RelB degradation following stimulation of T cells.
To prove a potential physical interaction between RelB and GSK-3b, we first analysed protein expression of RelB and different GSK-3b forms upon stimulation of Jurkat T cells with T þ I for defined time points (Figure 3a) . Expression of GSK-3b did not change upon stimulation (Figure 3a , third row). In contrast, a profound degradation of RelB was notable already 15 min after T þ I stimulation (Figure 3a, first row) . GSK-3b is inhibited by phosphorylation of serine 9 (S9), whereas phosphorylation of tyrosine 216 (Y216) activates this kinase. Thus, we performed immunoblots with Abs, differentially recognising one of the two phosphorylated GSK-3b forms (Doble and Woodgett, 2003; Forde and Dale, 2007) . However, no drastic changes in the expression levels of both the active and the inactive GSK-3b species were found (Figure 3a , rows 5 and 7). A slight increase of S9-phosphorylated GSK-3b was consistently present after prolonged stimulation. In contrast, the amount of Y216-phosphorylated GSK-3b was significantly elevated at early time points upon T þ I stimulation. Both findings correlate with the kinetics of RelB degradation (Figure 3a , row 1) and are thus in line with the hypothesis that active GSK-3b is a prerequisite for the signal-induced proteolysis of RelB. A comprehensive overview of the changes in RelB or GSK3-b expression upon T þ I stimulation of Jurkat cells is shown in Figure 3b .
To demonstrate a direct interaction between GSK-3b and RelB under physiological conditions, we performed immunoprecipitations (IPs) with RelB-and GSK-3b-specific Abs using whole-cellular protein from unstimulated Jurkat T cells or cells stimulated with T þ I for the indicated time points (Figure 3c ). All RelB-specific IPs were controlled by experiments performed with an excess of the immunogenic peptide used to raise the RelB-specific Ab (sc-226 P, Santa Cruz Biotechnology, Figure 3 RelB interacts with GSK-3b. (a) Immunoblot analysis of whole-cellular extracts from unstimulated Jurkat leukaemic T cells or cells stimulated with T þ I for the indicated times. The blots were probed with Abs against RelB (C19, sc-226, Santa Cruz Biotechnology), GSK-3b (#610202, BD Biosciences Pharmingen), pGSK-3b (S9) (#93365, Cell Signaling) or pGSK-3b (Y216) (BD Biosciences Pharmingen). Each blot was stripped and re-probed with an a-GAPDH Ab (V-18, sc-20357 HRP, Santa Cruz Biotechnology) as a control for equal loading. (b) Densitometric evaluation of three independent immunoblot experiments analysing the T þ I-induced expression of RelB and different GSK-3b species. The signal intensity of protein bands representing unstimulated cells was always set as 100%. The deviation of the signal intensities measured at each time point of stimulation was calculated as percent expression relative to this signal intensity. The mean values of these deviations detected in the three experiments were calculated for each time point and are presented in the graph. Standard deviations are displayed as bars. (c) IPs using whole-cellular extracts (400 mg protein per 500 ml total volume) from Jurkat T cells, either left unstimulated or stimulated with T þ I for the indicated time points. The IPs were performed using 1 mg of a RelB-(C-19, sc-226, Santa Cruz Biotechnology) or GSK-3b-specific Ab (#610202, BD Bioscience Pharmingen). The catch and release reversible immunoprecipitation system (v2.0) was used according to the protocol provided by the manufacturer (Millipore, Billerica, MA, USA). Elution of the immune complexes was performed using denaturing buffer. After resolution of the recovered RelB-or GSK-3b-specific immune complexes by PAGE (10% gel) and blotting, staining was performed using the indicated Abs described in (a). In addition, c-Rel-and RelA-specific Abs were used for probing (c-Rel (C), sc-71; NF-kB p65 (A), sc-109, both Santa Cruz Biotechnology). (d) Densitometric evaluation of three independent immunoprecipitation experiments analysing the T þ I-induced interaction of RelB with different GSK-3b species. This evaluation was performed as described in (b).
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Santa Cruz, CA, USA). GSK-3b IPs were tested for specificity performing the experiments without Ab. No GSK-3b-or RelB-specific signals were obtained in both types of control experiments (Figure 3c ). RelB degradation was confirmed probing the blotted RelB-specific immune complexes with a-RelB Abs (Figure 3c, row 1) . Interestingly, IPs performed with a-RelB and a-GSK-3b Abs showed that GSK-3b binds to RelB already in unstimulated cells (Figure 3c , rows 2 and 5). Increased binding of activated, Y216-phosphorylated GSK-3b to RelB was observed early upon stimulation (Figure 3c , row 4), whereas a significant RelB binding of the inhibited, S9-phosphorylated form of GSK-3b was only detectable at late time points (Figure 3c, row 3) , indicating differential kinetics of complex formation with RelB for these two GSK-3b species. The signal obtained for the S9-phosphorylated GSK-3b was rather weak, although the Ab worked well in immunoblot experiments (Figure 3a) , indicating that tyrosine phosphorylation of GSK-3b may selectively enhance binding to RelB. A previous study showed that activation of GSK-3b by tyrosine phosphorylation selectively contributes to the coxsackievirus B3-induced cytopathic effects and apoptosis in coxsackievirus B3-infected cells (Yuan et al., 2005) . However, as factors like the differential effectiveness of Abs in immunoblots compared with IPs should be taken into account, a possible control of RelB/GSK-3b interaction by tyrosine phosphorylation of GSK-3b has to be validated in additional studies. In control experiments, c-Rel did not interact with GSK-3b, whereas an inducible interaction of RelA with GSK-3b was found (Figure 3c ), indicating that an enzyme-substrate relationship might exist between both molecules as previously shown (Buss et al., 2004) . However, this interaction alone is not sufficient to prove such a relationship. No other kinase that was analysed interacted with RelB (Supplementary Figure  3) . The differences in the kinetics of RelB binding of the activated and inhibited form of GSK-3b are another indication that activation of GSK-3b is crucially involved in RelB degradation. The changes in interaction of the different GSK-3b forms with RelB upon T þ I stimulation are comprehensively shown in Figure 3d .
To further characterize the interrelationships between RelB and GSK-3b, we asked whether RelB is a substrate of GSK-3b in vitro. Putative GSK-3b phosphorylation sites of human RelB (hRelB) are displayed in the Supplementary Figure 4 . We first determined the activation of GSK-3b upon stimulation of Jurkat T cells with T þ I for different time points using an IP in vitro kinase assay with a GSK-3b-specific substrate peptide (Figure 4a ). GSK-3b already showed a substantial activity in unstimulated Jurkat T cells, and this activity was moderately induced with a peak between 25 and 40 min upon T þ I stimulation (Figure 4a) . We next performed IP kinase assays to uncover a substrateenzyme relationship between RelB and GSK-3b. As the degradation of IkB-a as well as RelB is phosphorylation dependent, we first performed in vitro kinase assays with immunoprecipitated IKK-g (NEMO)
from Jurkat T cells stimulated with T þ I for defined time points. GST-tagged IkB-a fragments containing wild-type or mutated IKK phosphorylation sites were used as substrates (Figure 4b ). The maximal inducible phosphorylation was notable at early time points (15 min after stimulation) correlating well with the early onset of IkB-a degradation (Figure 4b ). The observed phosphorylation was strongly reduced in control experiments using GST-tagged IkB-a fragments encompassing mutated phosphorylation sites or using a control Ab (a-p65/RelA) for IP, indicating the specificity of the reaction. Most importantly, we demonstrate using such IP kinase assays, that hRelB is indeed inducibly phosphorylated by GSK-3b in vitro (Figure 4c ). The assays were performed with GST-tagged full-length hRelB as a substrate. The kinetics of RelB phosphorylation differs from the kinetics of IkB-a phosphory lation. The strongest phosphorylation is reached later as compared with the IkB-a-specific kinase assay at 30 min after T þ I stimulation (Figure 4d ). In control experiments, the phosphorylation reaction was completely abolished by the specific GSK-3b inhibitor SB216763 (Figure 4c , lanes 7 and 8). This indicates that GSK-3b and not another co-precipitated kinase is responsible for the inducible phosphorylation of hRelB.
To identify a possible target site for GSK-3b-mediated RelB phosphorylation, we performed nonradioactive IP in vitro kinase assays, blotted the reaction mixtures and probed with an Ab, specific for RelB phosphorylated at Ser552. We found that hRelB is inducibly phosphorylated at Ser552 by GSK-3b in vitro (Figure 4d ). Ser552 is one of two phosphoacceptor sites identified in the murine RelB molecule in a previous study (Marienfeld et al., 2001) . The results of the three in vitro kinase assays are comprehensively displayed in Figure 4e . Most importantly, immunoblot analyses using the pRelB-specific Ab revealed that hRelB is also inducibly phosphorylated at Ser552 in vivo (Figure 4f ). Studies are planned to analyse GSK-3b-dependent phosphorylation of RelB in greater detail including investigations using primary T cells.
It was noticeable that hRelB was a much poorer substrate for GSK-3b compared with IKK-mediated phosphorylation of IkB-a. The exposure time was about 10 times longer as shown in the IkB-a-specific kinase assay. One reason could be that hRelB is per se a relative poor in vitro substrate of GSK-3b. b-Catenin is also weakly phosphorylated in vitro, because GSK-3b has a penchant for pre-phosphorylated (primed) substrates (Doble and Woodgett, 2003; Forde and Dale, 2007) . Priming of b-catenin by casein kinase I at Ser45 decreases the K m for GSK-3b by about 30-fold (Fiol et al., 1987; Forde and Dale, 2007) . However, previous work showed that priming phosphorylation is dispensable, especially when GSK-3b interacts with its substrate (Viatour et al., 2004) In conclusion, our work identifies GSK-3b as a crucial component of the pathways leading to signal-induced RelB degradation. This finding points to yet another mechanism, how GSK-3b can regulate the NF-kB system, a feature making it a potential target, especially in the therapy of cancer characterized by constitutive NF-kB activation (Ougolkov et al., 2007) . Figure 4 RelB is phosphorylated by GSK-3b. (a) GSK-3b activity assay. Assessment of GSK-3b activity in Jurkat leukaemic T cells stimulated with T þ I for the indicated time points was performed using the GSK-3b activity assay kit according to the manufacturer's instructions (Sigma-Aldrich). GSK-3b was immunoprecipitated using 400 mg protein lysate in a total volume of 500 ml. The immunoprecipitated kinase was incubated with 25 mCi of g-32
